Azenta (NASDAQ:AZTA - Get Free Report) is expected to be announcing its Q2 2025 earnings results before the market opens on Wednesday, May 7th. Analysts expect Azenta to post earnings of $0.09 per share and revenue of $140.87 million for the quarter.
Azenta (NASDAQ:AZTA - Get Free Report) last announced its earnings results on Wednesday, February 5th. The company reported $0.08 earnings per share for the quarter, beating the consensus estimate of $0.05 by $0.03. Azenta had a positive return on equity of 1.25% and a negative net margin of 24.91%. On average, analysts expect Azenta to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.
Azenta Trading Down 1.5 %
Shares of Azenta stock opened at $26.61 on Wednesday. Azenta has a 52 week low of $24.06 and a 52 week high of $63.58. The company's 50-day moving average price is $34.29 and its two-hundred day moving average price is $43.00. The stock has a market cap of $1.22 billion, a PE ratio of -8.93 and a beta of 1.66.
Analysts Set New Price Targets
Several research firms have issued reports on AZTA. TD Cowen raised Azenta to a "hold" rating in a report on Thursday, February 27th. Needham & Company LLC upped their price objective on shares of Azenta from $55.00 to $59.00 and gave the company a "buy" rating in a research note on Thursday, February 6th. Stephens reissued an "overweight" rating and issued a $60.00 price target on shares of Azenta in a research note on Thursday, January 2nd. Finally, Evercore ISI increased their target price on shares of Azenta from $50.00 to $52.00 and gave the stock an "in-line" rating in a research report on Thursday, February 6th.
Read Our Latest Research Report on Azenta
About Azenta
(
Get Free Report)
Azenta, Inc provides biological and chemical compound sample exploration and management solutions for the life sciences market in North America, Africa, China, the United Kingdom, rest of Europe, the Asia Pacific, and internationally. The company operates in two reportable segments, Life Sciences Products and Life Sciences Services.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Azenta, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Azenta wasn't on the list.
While Azenta currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
